Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study.

Front Reprod Health · 2025 · PMC12034626 · PMID 40297130

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

did not reach statistical significancep = 0.010actually significant

Group A: 0.1% (2/2,365)], though this difference did not reach statistical significance ( p = 0.010).The incidence rates of OHSS between the groups did not differ significantly.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.